Paper · 42955091

From forward-backward sweep to backpropagation for optimal control in tumor-immune dynamics.

Zhang W and 2 others. J Math Biol, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. From forward-backward sweep to backpropagation for optimal control in tumor-immune dynamics. Papers, record 42955091. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42955091

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: From forward-backward sweep to backpropagation for optimal control in tumor-immune dynamics.
Journal: J Math Biol
Year: 2026
Publication types: Journal Article
PubMed: https://pubmed.ncbi.nlm.nih.gov/42955091/
DOI: https://doi.org/10.1007/s00285-026-02475-2
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13719735/
The journal: https://conductscience.org/library/journal-index/7502105
Revised in PubMed: 2026-11-01

Source PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Zhang W	Wenjing	https://orcid.org/0000-0001-8779-5106
2	Ding W	Wandi
3	Zhu H	Huaiping

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Neoplasms	Major topic
Models, Immunological	Major topic
Mathematical Concepts
Neural Networks, Computer
Humans
Computer Simulation
Animals

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
A21-0013-001	Simons Foundation			PubMed
DGE-2510274	National Science Foundation			PubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References19

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	35,919,743	Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers.	Immunother Adv	2021	https://conductscience.org/library/papers/35919743	PubMed
2	20,160,101	PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.	Proc Natl Acad Sci U S A	2010	https://conductscience.org/library/papers/20160101	PubMed
3	37,509,725	Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging.	Biomedicines	2023	https://conductscience.org/library/papers/37509725	PubMed
4	33,818,908	Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.	CPT Pharmacometrics Syst Pharmacol	2021	https://conductscience.org/library/papers/33818908	PubMed
5	17,599,363	Optimal control of treatment in a mathematical model of chronic myelogenous leukemia.	Math Biosci	2007	https://conductscience.org/library/papers/17599363	PubMed
6	26,371,282	Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.	Ann Oncol	2015	https://conductscience.org/library/papers/26371282	PubMed
7	30,263,032	An introduction to immunology and immunopathology.	Allergy Asthma Clin Immunol	2018	https://conductscience.org/library/papers/30263032	PubMed
8	26,027,431	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.	N Engl J Med	2015	https://conductscience.org/library/papers/26027431	PubMed
9	34,477,976	Mathematical Model for Delayed Responses in Immune Checkpoint Blockades.	Bull Math Biol	2021	https://conductscience.org/library/papers/34477976	PubMed
10	33,608,375	In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity.	J Immunother Cancer	2021	https://conductscience.org/library/papers/33608375	PubMed

1 to 10 of 19

See all 19 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42955091

GET https://conductscience.org/api/papers/v1/42955091/authors

API reference For AI assistants